Petrelintide (ZP8396) is a dual amylin and calcitonin receptor agonist (DACRA) Petrelintide elicits a selective reduction in high-fat diet intake in diet-induced obese (DIO) rats, which is accompanied by a loss of fat mass and preservation of lean mass during weight reduction. Petrelintide can be utilized in diabetes research [1] [2] [3] [4].
In Vivo, Petrelintide (0.04 mg/kg, s.c., every third day for a total of 10 doses) reduces body weight and food intake in DIO rats[1]. Petrelintide (2 nmol/kg, s.c., every second day for 30 days, or 10 nmol/kg, s.c., every fourth day for 30 days) reduces food intake and body weight in DIO rats primarily by lowering intake of high fat diet[2]. Petrelintide (2 nmol/kg, s.c., every second day for 30 days, or 10 nmol/kg, s.c., every fourth day for 30 days) shows preferential fat mass loss and preservation of relative lean mass during weight loss in DIO rats[3].
In Vitro, Petrelintide demonstrates agonistic activity against hAMY3R and hCTR in HEK-293 cells, with EC50 of 2.997 and 9.215 nM, respectively[1].
References:
[1]. Zong L, et al. Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment. J Med Chem. 2025 Jul 24;68(14):14907-14918.
[2]. BILL V, et al. 1661-P: Petrelintide (ZP8396) Selectively Reduces Intake of High-Fat Diet in DIO Rats. Diabetes 14 June 2024; 73 (Supplement_1): 1661-P.
[3]. BILL V, et al. 1662-P: Petrelintide (ZP8396) Significantly Reduces Fat Mass while Preserving Lean Mass in DIO Rats. Diabetes 14 June 2024; 73 (Supplement_1): 1662-P.
[4]. JON G, et al. 1668-P: Novel Once-Weekly Amylin Analog Petrelintide (ZP8396) Is Well Tolerated with Improved GI Tolerability after Multiple Dosing, Diabetes, 2024;73(Supplement_1):1668-P
In Vivo, Petrelintide (0.04 mg/kg, s.c., every third day for a total of 10 doses) reduces body weight and food intake in DIO rats[1]. Petrelintide (2 nmol/kg, s.c., every second day for 30 days, or 10 nmol/kg, s.c., every fourth day for 30 days) reduces food intake and body weight in DIO rats primarily by lowering intake of high fat diet[2]. Petrelintide (2 nmol/kg, s.c., every second day for 30 days, or 10 nmol/kg, s.c., every fourth day for 30 days) shows preferential fat mass loss and preservation of relative lean mass during weight loss in DIO rats[3].
In Vitro, Petrelintide demonstrates agonistic activity against hAMY3R and hCTR in HEK-293 cells, with EC50 of 2.997 and 9.215 nM, respectively[1].
References:
[1]. Zong L, et al. Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment. J Med Chem. 2025 Jul 24;68(14):14907-14918.
[2]. BILL V, et al. 1661-P: Petrelintide (ZP8396) Selectively Reduces Intake of High-Fat Diet in DIO Rats. Diabetes 14 June 2024; 73 (Supplement_1): 1661-P.
[3]. BILL V, et al. 1662-P: Petrelintide (ZP8396) Significantly Reduces Fat Mass while Preserving Lean Mass in DIO Rats. Diabetes 14 June 2024; 73 (Supplement_1): 1662-P.
[4]. JON G, et al. 1668-P: Novel Once-Weekly Amylin Analog Petrelintide (ZP8396) Is Well Tolerated with Improved GI Tolerability after Multiple Dosing, Diabetes, 2024;73(Supplement_1):1668-P